menu
    • menu

    Company profile for Nova Mentis Life Science

    Suanfarma, at the Core of a Better Life.

    Virtual Booth

    Contact Supplier

    Jai Radhe Sales is your partner for all your sourcing needs.

    Virtual Booth

    Contact Supplier

    Centrient is a leading manufacturer of Beta-Lactam Antibiotics and a provider of next-generation Statins and Antifungals.

    Virtual Booth

    Contact Supplier

    Moehs Group, a reference company in the production of pharmaceutical active ingredients.

    Virtual Booth

    Contact Supplier

    Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    A Canadian-based public company that builds and supports a diversified portfolio of health and wellness businesses. Aiming to be an industry leader in the development of objective biologic endpoints to validate subjective behavioral changes in people receiving psychedelic therapy.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Nova Mentis Life ScienceCanada Flag
    Country
    Country
    Canada
    Address
    Address
    700-838 West Hasting Street Vancouver, B.C.
    Telephone
    Telephone
    778-819-0244
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.novamentis.ca/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Tides Asia

    Tides Asia

    Not Confirmed

    envelop Contact Supplier

    Tides Asia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    KGK Science Enters into Research Contract With Nova Mentis for Phase II A Trial
    KGK Science Enters into Research Contract With Nova Mentis for Phase II A Trial

    17 Nov 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20221117005145/en

    BUSINESSWIRE
    17 Nov 2022
    Share Share
    Nova Mentis Study Confirms Oral Microdose Psilocybin Treatment of Autism
    Nova Mentis Study Confirms Oral Microdose Psilocybin Treatment of Autism

    16 Feb 2022

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/nova-mentis-study-confirms-oral-microdose-psilocybin-treatment-of-autism-301483609.html

    PRNEWSWIRE
    16 Feb 2022
    Share Share
    Nova Mentis Files Genetic Neuroinflammatory Disease Patent
    Nova Mentis Files Genetic Neuroinflammatory Disease Patent

    09 Nov 2021

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/nova-mentis-files-genetic-neuroinflammatory-disease-patent-301419509.html

    PRNEWSWIRE
    09 Nov 2021
    Share Share
    Nova Mentis Applies to US FDA for Psilocybin Orphan Drug Designation
    Nova Mentis Applies to US FDA for Psilocybin Orphan Drug Designation

    14 Sep 2021

    // YAHOO

    https://finance.yahoo.com/news/nova-mentis-applies-us-fda-140700565.html

    YAHOO
    14 Sep 2021
    Share Share
    Nova Mentis Expands Psilocybin Research Program Targets Obesity and Diabetes
    Nova Mentis Expands Psilocybin Research Program Targets Obesity and Diabetes

    07 Sep 2021

    // PRNEWSWIRE

    https://www.newswire.ca/news-releases/nova-mentis-expands-psilocybin-research-program-targets-obesity-and-diabetes-858128691.html

    PRNEWSWIRE
    07 Sep 2021
    Share Share
    Nova Mentis Files Fragile X Orphan Drug Designation with EMA
    Nova Mentis Files Fragile X Orphan Drug Designation with EMA

    12 Aug 2021

    // NEWSWIRE

    https://www.newswire.ca/news-releases/nova-mentis-files-fragile-x-orphan-drug-designation-with-european-medicines-agency-849104337.html

    NEWSWIRE
    12 Aug 2021
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search